Literature DB >> 16519548

Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias.

Jerrold Hill1, Howard Fillit, Simu K Thomas, Sobin Chang.   

Abstract

INTRODUCTION: The progressive decline in functional status for patients with Alzheimer's disease and other dementias (ADOD) is well documented. However, there is limited information on the economic benefits of interventions improving functional status in an ADOD population. This study estimated the relationship between the degree of functional impairment in patients with ADOD and their healthcare costs and prevalence of institutionalisation.
METHODS: Retrospective cross-sectional analyses of the Medicare Current Beneficiary Survey (MCBS) were performed. A nationally representative sample of Medicare beneficiaries with ADOD was identified from the 1995-8 waves of the MCBS (n = 3138): 34% in the community, 57% institutionalised and 9% residing in both settings during the year. Three measures of functioning were used: the number of activities of daily living (ADLs) and independent ADLs (IADLs) impaired; an index summarising number and severity of ADL and IADL impairments; and the Katz Index of ADLs. Healthcare costs included costs for all healthcare services received in all settings, regardless of whether they were covered by insurance or paid out of pocket. The relationships between each measure of impairment and healthcare costs and prevalence of institutionalisation were estimated using linear and logistic regression.
RESULTS: Healthcare costs (1995-8 values) for all ADOD patients increased by 1,958 US dollars (p < 0.001) for each additional ADL impairment and 549 US dollars (p = 0.073) for each additional IADL impairment. For community-dwelling ADOD patients, healthcare costs increased by 1,541 US dollars (p < 0.001) for each additional ADL and 714 US dollars (p = 0.022) for each additional IADL. Costs also increased by severity on the summary index and the Katz Index. Odds of institutionalisation also increased by the three measures of functional impairment.
CONCLUSION: Although relationships between function and costs have been described previously, the exact nature of these relationships has not been investigated solely in patients with dementia. The data from this study suggest a strong relationship between functional impairment and healthcare costs, specifically in patients with dementia. Even IADL impairments, which are common in mild to moderate dementia, may significantly raise costs. The results suggest that therapies and care management that improve functioning may possibly reduce other healthcare costs.

Entities:  

Mesh:

Year:  2006        PMID: 16519548     DOI: 10.2165/00019053-200624030-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  27 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  D Galasko; D Bennett; M Sano; C Ernesto; R Thomas; M Grundman; S Ferris
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

Review 3.  Economic research on Alzheimer disease: a review of the literature.

Authors:  R L Ernst; J W Hay
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

4.  The effect of donepezil therapy on health costs in a Medicare managed care plan.

Authors:  Jerrold W Hill; Robert Futterman; Vera Mastey; Howard Fillit
Journal:  Manag Care Interface       Date:  2002-03

5.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

6.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

7.  Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.

Authors:  Douglas Galasko; Paul R Kershaw; Lon Schneider; Young Zhu; Pierre N Tariot
Journal:  J Am Geriatr Soc       Date:  2004-07       Impact factor: 5.562

8.  Utility of Mini-Mental State Exam scores in predicting functional impairment among white and African American dementia patients.

Authors:  G R Ford; W E Haley; S L Thrower; C A West; L E Harrell
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1996-07       Impact factor: 6.053

Review 9.  Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland Scale for Activities of Daily Living.

Authors:  M B Patterson; J L Mack; M M Neundorfer; R J Martin; K A Smyth; P J Whitehouse
Journal:  Alzheimer Dis Assoc Disord       Date:  1992       Impact factor: 2.703

10.  The economic burden of Alzheimer's disease care.

Authors:  D P Rice; P J Fox; W Max; P A Webber; D A Lindeman; W W Hauck; E Segura
Journal:  Health Aff (Millwood)       Date:  1993       Impact factor: 6.301

View more
  27 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

3.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 4.  Dependence as a unifying construct in defining Alzheimer's disease severity.

Authors:  Trent McLaughlin; Howard Feldman; Howard Fillit; Mary Sano; Frederick Schmitt; Paul Aisen; Christopher Leibman; Lisa Mucha; J Michael Ryan; Sean D Sullivan; D Eldon Spackman; Peter J Neumann; Joshua Cohen; Yaakov Stern
Journal:  Alzheimers Dement       Date:  2010-11       Impact factor: 21.566

5.  Association of Sensory and Cognitive Impairment With Healthcare Utilization and Cost in Older Adults.

Authors:  William James Deardorff; Phillip L Liu; Richard Sloane; Courtney Van Houtven; Carl F Pieper; Susan Nicole Hastings; Harvey J Cohen; Heather E Whitson
Journal:  J Am Geriatr Soc       Date:  2019-03-29       Impact factor: 5.562

6.  Caregiver burden, health utilities, and institutional service use in Alzheimer's disease.

Authors:  Edward Alan Miller; Robert A Rosenheck; Lon S Schneider
Journal:  Int J Geriatr Psychiatry       Date:  2011-05-10       Impact factor: 3.485

Review 7.  Methodological issues in using multiple years of the Medicare current beneficiary survey.

Authors:  Becky A Briesacher; Jennifer Tjia; Chyke A Doubeni; Yong Chen; Sowmya R Rao
Journal:  Medicare Medicaid Res Rev       Date:  2012-02-08

8.  A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial.

Authors:  Laura N Gitlin; Laraine Winter; Marie P Dennis; Nancy Hodgson; Walter W Hauck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

9.  The effects of patient function and dependence on costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

10.  Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.

Authors:  Kaycee M Sink; Joseph Thomas; Huiping Xu; Bruce Craig; Steven Kritchevsky; Laura P Sands
Journal:  J Am Geriatr Soc       Date:  2008-04-01       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.